FORM 4
☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

AYERS JONATHAN W		 2. Issuer Name and Ticker or Trading Symbol

IDEXX LABORATORIES INC /DE [ IDXX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

ONE IDEXX DRIVE		 3. Date of Earliest Transaction (MM/DD/YYYY)

5/18/2023
(Street)

WESTBROOK, ME 04092		 4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)        (State)        (Zip)
Rule 10b5-1(c) Transaction Indication
☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 5/18/2023  M  10000 A$79.54 147039 D  
Common Stock 5/18/2023  S  1000 D$486.482 (1)146039 D  
Common Stock 5/18/2023  S  2753 D$487.8353 (2)143286 D  
Common Stock 5/18/2023  S  1012 D$488.6343 (3)142274 D  
Common Stock 5/18/2023  S  2242 D$489.7081 (4)140032 D  
Common Stock 5/18/2023  S  1695 D$490.7719 (5)138337 D  
Common Stock 5/18/2023  S  1298 D$491.9058 (6)137039 D  
Common Stock 5/19/2023  M  10000 A$79.54 147039 D  
Common Stock 5/19/2023  S  1138 D$486.9211 (7)145901 D  
Common Stock 5/19/2023  S  2254 D$487.8169 (8)143647 D  
Common Stock 5/19/2023  S  1308 D$488.7748 (9)142339 D  
Common Stock 5/19/2023  S  300 D$490.0283 (10)142039 D  
Common Stock 5/19/2023  S  400 D$491.59 (11)141639 D  
Common Stock 5/19/2023  S  1426 D$492.8167 (12)140213 D  
Common Stock 5/19/2023  S  1229 D$494.276 (13)138984 D  
Common Stock 5/19/2023  S  886 D$495.9351 (14)138098 D  
Common Stock 5/19/2023  S  759 D$497.6556 (15)137339 D  
Common Stock 5/19/2023  S  300 D$498.48 (16)137039 D  
Common Stock         450000 I by Jonathan W. Ayers 2022 GRAT (17)
Common Stock         10000 I by Ayers Family Trust 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (right-to-buy) $79.54 5/18/2023  M     10000   (18)2/13/2025 Common Stock 10000.0  (19)105540 D  
Non-Qualified Stock Option (right-to-buy) $79.54 5/19/2023  M     10000   (18)2/13/2025 Common Stock 10000.0  (19)95540 D  
Explanation of Responses:
(1) Represents the weighted average price of the shares sold ranging from a low of $486.08 to a high of $487.03 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(2) Represents the weighted average price of the shares sold ranging from a low of $487.19 to a high of $488.19 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(3) Represents the weighted average price of the shares sold ranging from a low of $488.21 to a high of $489.02 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(4) Represents the weighted average price of the shares sold ranging from a low of $489.32 to a high of $490.32 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(5) Represents the weighted average price of the shares sold ranging from a low of $490.375 to a high of $491.30 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(6) Represents the weighted average price of the shares sold ranging from a low of $491.54 to a high of $492.345 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(7) Represents the weighted average price of the shares sold ranging from a low of $486.29 to a high of $487.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(8) Represents the weighted average price of the shares sold ranging from a low of $487.34 to a high of $488.32 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(9) Represents the weighted average price of the shares sold ranging from a low of $488.41 to a high of $489.35 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(10) Represents the weighted average price of the shares sold ranging from a low of $489.865 to a high of $490.11 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(11) Represents the weighted average price of the shares sold ranging from a low of $491.36 to a high of $491.74 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(12) Represents the weighted average price of the shares sold ranging from a low of $492.38 to a high of $493.31 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(13) Represents the weighted average price of the shares sold ranging from a low of $493.37 to a high of $494.53 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(14) Represents the weighted average price of the shares sold ranging from a low of $495.53 to a high of $496.45 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(15) Represents the weighted average price of the shares sold ranging from a low of $497.00 to a high of $497.99 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(16) Represents the weighted average price of the shares sold ranging from a low of $498.47 to a high of $498.50 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(17) The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT (the "GRAT"). The GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
(18) Grant of option to buy 74,316 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
(19) Not applicable.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
AYERS JONATHAN W
ONE IDEXX DRIVE
WESTBROOK, ME 04092		X
Signatures
/s/ Lily J. Lu, Attorney-in-Fact for Jonathan W. Ayers5/22/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Grafico Azioni IDEXX Laboratories (NASDAQ:IDXX)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di IDEXX Laboratories
Grafico Azioni IDEXX Laboratories (NASDAQ:IDXX)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di IDEXX Laboratories